The combinations sold for weight loss, for women too: what the CagriSema trials report, what AOD-9604, MOTS-c and 5-Amino-1MQ lack, and the units per draw.
This page reports the peptide combinations sold for weight loss, including the ones marketed to women: what each component is, who claims what, what the human evidence holds when it is counted, the reported doses with their sources, and how the vials are reconstituted and drawn. It ranks nothing and presents no protocol. Every figure carries its source and the date it was read.
Two kinds of compound appear in these stacks. The first is the incretin drugs: semaglutide, a GLP-1 receptor agonist, and tirzepatide, a GIP and GLP-1 receptor agonist, both approved and labelled for weight management, and cagrilintide, an investigational long-acting analogue of amylin, a hormone released with insulin that slows stomach emptying and signals fullness. The second is the compounds sold beside them with no human trial result: AOD-9604, a fragment of growth hormone; MOTS-c, a 16-amino-acid peptide encoded in mitochondrial DNA; and 5-Amino-1MQ, a small molecule sold as a capsule that inhibits the enzyme NNMT. The only combination in this list with trials of the pair is cagrilintide with semaglutide, and it has its own page: cagrilintide and GLP-1.
What is sold as a weight-loss stack, and by whom
The first page of results for "best peptide stack for weight loss", with and without "female", is telehealth clinics, med-spa blogs and a women-over-40 fitness site (read 2026-09-18). The recurring claims: a GLP-1 drug "for appetite" with CJC-1295 and ipamorelin "for body composition"; AOD-9604 added "for stubborn fat", sometimes with semaglutide; MOTS-c "for metabolism"; 5-Amino-1MQ "for fat cells". The women's pages differ from the men's in wording, not in compounds: the same GLP-1 drug and the same secretagogue pairing, with AOD-9604 or tesamorelin as the third item. No page in that set cites a trial of the combination it sells, and the combinations built on growth-hormone secretagogues are counted on the muscle-growth stack page, where the same zero appears.
The combination with trials: cagrilintide with a GLP-1
| Trial |
Registration |
Participants |
Duration |
What was compared |
Result (body weight) |
| Phase 1b (Enebo et al., Lancet 2021) |
NCT03600480 |
96 |
20 weeks |
cagrilintide 0.16 to 4.5 mg with semaglutide 2.4 mg, co-escalated in four-week steps over 16 weeks, against placebo with semaglutide |
safety and pharmacokinetics were the endpoints |
| Phase 2 in type 2 diabetes (Frias et al., Lancet 2023) |
NCT04982575 |
92 |
32 weeks |
CagriSema 2.4 mg each, semaglutide 2.4 mg, cagrilintide 2.4 mg |
15.6% against 5.1% and 8.1% |
| REDEFINE 1 (Garvey et al., NEJM 2025) |
NCT05567796 |
3,417 |
68 weeks |
CagriSema 2.4 mg each, each drug alone, placebo |
20.4% against 3.0% on placebo |
| REDEFINE 2 (Davies et al., NEJM 2025) |
NCT05394519 |
1,206 |
68 weeks |
CagriSema 2.4 mg each against placebo, in type 2 diabetes |
13.7% against 3.4% |
| REDEFINE 4 (Novo Nordisk announcement, 2026-02-23) |
NCT06131437 |
809 |
84 weeks |
CagriSema 2.4 mg each against tirzepatide 15 mg |
20.2% against 23.6%; non-inferiority not met |
| Cagrilintide alone, dose-finding (Lau et al., Lancet 2021) |
NCT03856047 |
706 |
26 weeks |
0.3, 0.6, 1.2, 2.4 or 4.5 mg weekly, liraglutide 3 mg, placebo |
dose-response; the source of the 2.4 mg figure |
ClinicalTrials.gov held 44 registrations naming cagrilintide as an intervention on 2026-09-18, every one sponsored by Novo Nordisk, 35 of them with semaglutide. Novo Nordisk filed CagriSema with FDA in December 2025 (company release of 2025-12-22 as carried by drugs.com); no regulator had approved it on 2026-09-18, and no cagrilintide product has a label.
The components without trials
| Component |
Label |
ClinicalTrials.gov (2026-09-18) |
PubMed (2026-09-18) |
Circulating figure (read 2026-09-18) |
| AOD-9604 |
none (DailyMed: zero) |
0 registrations |
22 records; 0 under the trial filter |
300 mcg a day under the skin; some pages 250 to 500 mcg |
| MOTS-c |
none |
1 administering study, NCT07505745, phase 2a, recruiting, dose not stated; 4 others measure it as a marker |
145 human-tagged records; 5 under the trial filter, all measuring endogenous MOTS-c |
5 to 10 mg a week in two or three injections |
| 5-Amino-1MQ |
none |
0 registrations |
4 records, all mice or cells |
50 to 150 mg a day by capsule |
Two details from those rows. The MOTS-c registration is a Hudson Biotech study of 120 planned adults with prediabetes, a fixed subcutaneous dose once daily for 12 weeks, started 2026-02-02 with primary completion planned for 2027; the record gives no dose, so no MOTS-c figure on any page traces to it. The five MOTS-c papers under the trial filter are studies of heat stress, breast cancer and exercise that measured circulating MOTS-c in participants who were given something else. AOD-9604's 22 records are largely anti-doping analytical chemistry, and 5-Amino-1MQ's four are two mouse metabolic papers, one cancer-fibroblast paper and one cell-line paper; Peptifact's 5-Amino-1MQ page lists all four.
The labelled doses in these stacks
The GLP-1 half of every stack has a label, and the label is the one dose source in this article that is neither a trial nor a marketing page. WEGOVY (semaglutide, revised 6/2026): 0.25 mg weekly for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, then a maintenance dose of 1.7 or 2.4 mg, with 7.2 mg as a maximum for patients who tolerate 2.4 mg for at least four weeks. ZEPBOUND (tirzepatide, revised 8/2026): 2.5 mg weekly for four weeks, then 2.5 mg increments after at least four weeks at each step, to 5, 10 or 15 mg. Both labels read on DailyMed on 2026-09-18. The site's semaglutide and tirzepatide calculators work those figures for research vials.
Reconstitution and the units per draw
Concentration is the milligrams in the vial divided by the millilitres of water; the draw on a U-100 syringe is the quantity in mg divided by that concentration, times 100. The vial sizes are the ones the site's calculators carry.
| Vial |
Water |
Concentration |
Quantity |
Units (U-100) |
| Cagrilintide 5 mg |
1 mL |
5 mg/mL |
0.3 mg |
6 units |
| same vial |
1 mL |
5 mg/mL |
2.4 mg |
48 units |
| Cagrilintide 10 mg |
2 mL |
5 mg/mL |
4.5 mg |
90 units |
| Semaglutide 5 mg |
2 mL |
2.5 mg/mL |
0.25 mg |
10 units |
| same vial |
2 mL |
2.5 mg/mL |
2.4 mg |
96 units |
| Tirzepatide 10 mg |
2 mL |
5 mg/mL |
2.5 mg |
50 units |
| same vial |
2 mL |
5 mg/mL |
5 mg |
100 units |
| AOD-9604 5 mg |
2 mL |
2.5 mg/mL |
300 mcg |
12 units |
| MOTS-c 10 mg |
2 mL |
5 mg/mL |
5 mg |
100 units |
| MOTS-c 10 mg |
1 mL |
10 mg/mL |
5 mg |
50 units |
| 5-Amino-1MQ 50 mg vial |
2 mL |
25 mg/mL |
50 mg |
200 units, two syringes |
Two vials mean two draws and two calculations; the blend calculator does both, and the per-compound calculators cover each vial: cagrilintide, AOD-9604, MOTS-c and 5-Amino-1MQ, whose vial arithmetic applies to the lyophilized presentation and not to the capsule. The 5-Amino-1MQ row shows why the capsule dominates: 50 mg is two full syringes at 25 mg/mL. The scales and barrels are on the insulin syringe units page.
The CagriSema figures omit the research vial: the trials used pen devices, a 16-week escalation and lifestyle intervention in every arm, and the result belongs to that programme. The label figures omit the combination: WEGOVY and ZEPBOUND are labelled alone. The circulating figures for AOD-9604, MOTS-c and 5-Amino-1MQ omit any human study at all, so route, frequency, duration and population are unstudied for each of them, not merely unreported. And the phrase "for women" omits a trial of its own, because there is none; it names the same compounds under a different heading.
Related pages
The cagrilintide and GLP-1 page works the CagriSema programme and the tirzepatide question in full; the muscle-growth stack page counts the secretagogue pairings these stacks borrow; the stacks hub indexes every combination; the dosage pages for cagrilintide, semaglutide, tirzepatide, AOD-9604 and MOTS-c hold each compound's reported range, indexed on the dosage hub. The component guides on the store: Medibact's cagrilintide guide, semaglutide guide, tirzepatide guide, AOD-9604 guide, MOTS-c guide and 5-Amino-1MQ guide.
This page does not recommend a stack, a dose, a schedule or a vendor, for women or for anyone. It reports what trials, labels, registries and the promoting pages state, each with its date, and it does the arithmetic on the vials.
Sources and dates
Opened 2026-09-18: the abstracts of PMID 40544433, 40544432, 37364590, 33894838, 34798060 and 42251859 via the NCBI E-utilities; the ClinicalTrials.gov v2 API for cagrilintide, AOD-9604, MOTS-c and 5-Amino-1MQ, and the records NCT05567796, NCT05394519, NCT06131437, NCT03856047, NCT04982575 and NCT07505745; PubMed counts with the trial-type filter for AOD-9604, MOTS-c (titles retrieved) and 5-Amino-1MQ; the DailyMed SPL search API for the four compounds (zero records each) and the WEGOVY and ZEPBOUND labels; the REDEFINE 4 result as reported by STAT (2026-02-23) and HCPLive; the CagriSema filing as carried by drugs.com (2025-12-22); telehealth, med-spa and protocol pages carrying the circulating figures. Corrections go to the contact page.
